FDA bans another Ranbaxy plant

Share this article:

Ranbaxy's US woes continue. The FDA announced Friday that it has now banned drugs from the firm's Toansa, India, facility. As noted by Bloomberg, this is now the fourth Ranbaxy manufacturing site that's a no-go in terms of providing products to the US. The latest reason: FDA inspectors found workers manipulated testing results so that failed drugs passed testing requirements.

The FDA ban's reach is pretty substantial because it bars fully manufactured drugs from entering the US, in addition to preventing US facilities from incorporating active ingredients from the facility into US-produced items.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.